热门资讯> 正文
Leap Therapeutics GAAP每股收益为-0.37美元
2025-05-13 19:45
- Leap Therapeutics press release (NASDAQ:LPTX): Q1 GAAP EPS of -$0.37.
- Cash and cash equivalents totaled $32.7 million at March 31, 2025.
More on Leap Therapeutics
- Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript
- DKN-01 DeFianCe Data Update
- Seeking Alpha’s Quant Rating on Leap Therapeutics
- Historical earnings data for Leap Therapeutics
- Financial information for Leap Therapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。